Series B Round

Granite Bio has raised $70 million in a Series B funding round to advance its innovative immunology assets. The company is focusing on developing first-in-class therapeutic antibodies that target inflammation, autoimmunity, and fibrosis by addressing the fundamental drivers of these diseases at their source. This funding will support the development of two antibody therapies aimed at treating multiple autoimmune diseases, including ulcerative colitis. The funding round was co-led by Versant Ventures and included participation from notable investors such as Novartis, Forbion, and Sanofi, bringing the total raised by Granite Bio to $100 million across its Series A and B rounds. Granite Bio is pioneering a new approach to immunology, emphasizing the depletion of pathogenic cells to provide effective treatments.